Target Blood Pressure in Gestational Hypertension
For gestational hypertension, the target blood pressure is a diastolic BP of 85 mmHg and systolic BP of 110-140 mmHg in the office setting (or <135/85 mmHg at home), with treatment initiated when BP is consistently ≥140/90 mmHg in clinic or ≥135/85 mmHg at home. 1
Treatment Initiation Threshold
Treatment should begin when blood pressure reaches or exceeds:
- Office/clinic measurements: ≥140/90 mmHg
- Home measurements: ≥135/85 mmHg
This applies to all hypertensive disorders of pregnancy, including gestational hypertension 1.
Target Blood Pressure Range
The evidence strongly supports targeting:
- Diastolic BP: 85 mmHg (office setting)
- Systolic BP: 110-140 mmHg (office setting)
- Lower safety limit: Reduce or cease antihypertensive drugs if diastolic BP falls <80 mmHg 1
This target is based on the highest-quality randomized trial (CHIPS) that demonstrated tight diastolic control (target 85 mmHg) significantly reduced severe maternal hypertension without adverse fetal outcomes 2. The 2025 AHA/ACC guidelines specifically reference this evidence, noting that tight DBP control to 85 mmHg reduced severe hypertension with no significant differences in maternal, fetal, or neonatal complications 2.
Rationale for This Target
The target of 85 mmHg diastolic is designed to:
- Reduce severe maternal hypertension (>160/110 mmHg), which carries significant risk of stroke, renal injury, and other complications
- Prevent progression to preeclampsia (approximately 25-30% of gestational hypertension cases progress to preeclampsia) 1, 2
- Avoid excessive BP lowering that could impair uteroplacental perfusion and fetal growth 1
Recent meta-analysis data from 2025 confirms that targeting <140/90 mmHg significantly reduces risks of severe hypertension, preeclampsia, and preterm birth at <37 weeks 3.
Severe Hypertension Requires Urgent Treatment
Critical threshold: BP ≥160/110 mmHg requires urgent treatment in a monitored setting within 30-60 minutes 1, 2, 4. This is considered a hypertensive emergency in pregnancy due to stroke risk.
Acceptable agents for acute severe hypertension include:
- Oral immediate-release nifedipine (10-20 mg, onset 5-10 minutes)
- IV labetalol (10-20 mg bolus, onset 1-2 minutes)
- IV hydralazine (5 mg, onset 10-20 minutes) 2
First-Line Maintenance Antihypertensive Agents
For chronic BP control in gestational hypertension, acceptable first-line agents include 1:
- Oral methyldopa
- Oral labetalol
- Oral nifedipine (extended-release preferred)
- Oral oxprenolol
Avoid: ACE inhibitors, ARBs, direct renin inhibitors, and atenolol (associated with fetal growth restriction) 2, 4.
Important Clinical Caveats
Gestational hypertension is not benign: At least 25-30% will progress to preeclampsia, with highest risk when diagnosed <34 weeks 1, 2. Therefore, close monitoring is essential even when BP is controlled.
Hospital assessment required if:
- Severe hypertension develops (≥160/110 mmHg)
- Features of preeclampsia emerge (proteinuria, symptoms, laboratory abnormalities) 1
Home BP monitoring is valuable: It improves BP ascertainment and can be combined with telehealth for postpartum management, potentially reducing disparities in care 2.
The evidence from ISSHP (International Society for the Study of Hypertension in Pregnancy) guidelines 1 represents the most comprehensive and widely-adopted international consensus, supported by the 2025 AHA/ACC guidelines 2, 4, 2 which specifically endorse the 85 mmHg diastolic target based on the CHIPS trial data.